Bd receives 510(k) clearance for covid-19, influenza a/b, rsv molecular combination test

Single test on bd max™ system identifies and differentiates multiple respiratory infectious diseases from one sample franklin lakes, n.j. , aug. 1, 2023 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced u.s. food and drug administration (fda) 510(k) clearance for the bd respiratory viral panel (rvp) for bd max™ system, a single molecular diagnostic combination test that identifies and distinguishes sars-cov-2, influenza a, influenza b, and respiratory syncytial virus (rsv) in approximately two hours.
BDX Ratings Summary
BDX Quant Ranking